Basket cover image
15 handpicked stocks

AI's Billion-Dollar Breakthrough

Palantir's record-breaking $1 billion revenue quarter showcases the immense growth in the artificial intelligence sector. This trend creates a significant opportunity for companies that provide the foundational technology, including AI software, semiconductor hardware, and cloud infrastructure.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at अगस्त 5

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

NVDA

NVIDIA Corporation

NVDA

Current price

$175.64

MSFT

Microsoft Corporation

MSFT

Current price

$509.77

GOOGL

Alphabet Inc (Google)

GOOGL

Current price

$201.57

About This Group of Stocks

1

Our Expert Thinking

Palantir's record-breaking £1 billion revenue quarter demonstrates the massive commercial potential of artificial intelligence. This milestone signals that AI has moved beyond experimental phases into widespread business adoption, creating opportunities across the entire technology ecosystem that powers these sophisticated systems.

2

What You Need to Know

This group focuses on the foundational technology providers that enable AI growth - from semiconductor manufacturers and cloud infrastructure giants to software innovators. These companies form the backbone of the AI revolution, providing the essential hardware, platforms, and services that make advanced AI applications possible.

3

Why These Stocks

These stocks were handpicked by professional analysts based on their strategic positioning within the AI value chain. Each company plays a crucial role in supporting the expanding AI ecosystem, from chip designers and cloud computing leaders to software platforms that enable AI deployment across industries.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+8.39%

Group Performance Snapshot

8.39%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 8.39% over the next year.

11 of 15

Stocks Rated Buy by Analysts

11 of 15 assets in this group are rated Buy by professional analysts.

1.5%

Group Growth

This group averaged a 1.5% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🚀

Riding the AI Revenue Wave

Palantir's billion-dollar milestone proves AI is generating serious commercial returns. Companies in this space are experiencing unprecedented demand as businesses rush to integrate AI capabilities.

Infrastructure Gold Rush

As AI adoption accelerates, the demand for powerful semiconductors, cloud computing, and specialised hardware is surging. These foundational companies are positioned at the centre of this technological transformation.

💎

Expert-Curated AI Leaders

This collection features the companies that analysts believe are best positioned to capitalise on the AI boom. From chip giants to cloud innovators, these are the names driving the industry forward.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.